BCLI Brainstorm Cell Therapeutics Inc. featured news, full reports, and detailed charts
Brainstorm Cell Therapeutics Inc. (BCLI/BCLI.OB) Wrap Up:
Brainstorm Cell Therapeutics, Inc. develops adult stem cell therapeutic products derived from autologous (self) bone marrow cells for the treatment of neurodegenerative diseases. Its NurOwn technology (patent pending technology) allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University, Ltd. Its primary focus is on Parkinson ALS and Spinal Cord Injury, as well as several others diseases, including MS, Huntington's disease, and stroke. The company was formerly known as Golden Hand Resources, In...www.brainstorm-cell.com
4 Employees
Founded in 2000
Brainstorm Cell Therapeutics Inc. (BCLI:OTC Bulletin Board Market)
LAST $0.30 USD
CHANGE TODAY 0.00 0.00%
VOLUME 62.9K
As of 3:56 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Brainstorm Cell Therapeutics Inc. (BCLI)
|
OPEN
$0.30
|
PREVIOUS CLOSE
$0.30
|
|
|
DAY HIGH
$0.30
|
DAY LOW
$0.29
|
|
|
52 WEEK HIGH
09/25/09 - $0.49
|
52 WEEK LOW
07/20/09 - $0.05
|
|
|
MARKET CAP
21.6M
|
AVERAGE VOLUME 3 mo
301.7K
|
|
|
DILUTED EPS TTM
$-0.02
|
SHARES OUTSTANDING
72.0M
|
|
|
BCLI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
BCLI Top Compensated Officers
Mr. Abraham Efrati
Chief Executive Officer
Age: 59
Total Annual Compensation: $179.9K
Mr. Chaim Lebovits
President
Age: 38
Total Annual Compensation: $56.4K
Mr. David Stolick CPA
Chief Financial Officer and Principal Account...
Age: 43
Total Annual Compensation: $104.8K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Brainstorm Cell Therapeutics Inc. (BCLI)
Brainstorm Cell Therapeutics Inc. - Conference Presentation Call
10/19/2009
To discuss the company, its technology and its progress towards clinical trials
Brainstorm Cell Therapeutics Inc. Provides Update on ALS Clinical Trials
10/5/2009
Brainstorm Cell Therapeutics Inc. announced that bone marrow cells taken from ALS patients were capable of differentiating into nerve-supporting cells. The company tested ALS patients' bone marrow stem cells in order to confirm that these stem cells could undergo BrainStorm’s differentiation procedure to secrete NeuroTrophic Factors (NTF) and used for treatment by back transplantation into the patients. The experiments performed at BrainStorm Cell Therapeutics’ research laboratories showed that the stem cells isolated from bone marrow of healthy donors and ALS patients were similar, as indicated by all the morphological and biochemical parameters tested. In addition, the cellular expansion potential of stem cells from the healthy donors and from the patients was comparable. Most important, cells from both, the healthy donors and the patients, secreted NeuroTrophic Factors (NTF) after applying Brainstorm’s unique differentiation protocols. BrainStorm will now complete all of its preparations for pre-clinical trials to be followed by clinical trials based on the company's proposed stem cell therapy.
Brainstorm Cell Therapeutics Enters into Strategic Agreement with Harlan Biotech
09/15/2009
Brainstorm Cell Therapeutics Inc. announced that it has entered into a strategic agreement with Harlan Biotech Israel Ltd. (HBI) in order to complete pre-clinical safety experiments for the company's innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's disease). This agreement, together with the agreement entered by Brainstorm with PPS will allow Brainstorm to complete the experiments required to submit an application to the Helsinki Committee with the Israeli Ministry of Health for starting ALS clinical trials in Israel. Under the agreement with Harlan, HBI will perform pre-clinical safety experiments using the company's cGMP compliant stem cells. The experiment will be performed immediately following production of the company's cGMP compliant stem cells which is currently performed by Brainstorm's scientists at PPS facilities. The production process is scheduled to extend over a period of several months, however the company has entered into the agreement with HBI in order to ensure that the necessary preparations are performed by HBI and that the safety experiments will commence at HBI without further delay.
BCLI Competitors
| Company | Last | Change | |
| No competitor information is available for BCLI. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | BCLI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
BCLI |
||
|
BCLI transactions
| Type Date |
Target |
|
Private Placement
August 24, 2009 |
-- |
More Recent News About Brainstorm Cell Therapeutics Inc.
More news for BCLI
BRAINSTORM CELL THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report contains numerous statements, descriptions, forecasts and projections, regarding Brainstorm Cell Therapeutics Inc. and its potential future business operations and performance. These statements, descriptions, forecasts and projections constitute "forward-looking statements," and as such involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance and achievements to be materially different from any results, levels of activity, performance and achievements expressed or implied by any such "forward-looking statements." Some of these are described under "Risk Factors" in this report and in our annual report on Form 10-K for the fiscal year ended December 31, 2008 and in our quarterly report on Form10-Q for the fiscal quarter ended June 30, 2009. In some cases you can identify such "forward-looking statements" by the use of words like "may," "will," "should," "could," "expects," "hopes," "anticipates," "believes," "intends," "plans," "estimates," "predicts," "likely," "potential," or "continue" or the negative of any of these terms or similar words. These "forward-looking statements" are based on certain assumptions that we have made as of the date hereof. To the extent these assumptions are not valid, the associated "forward-looking statements" and projections will not be correct. Although we believe that the expectations reflected in these "forward-looking statements" are reasonable, we cannot guarantee any future results, levels of activity, performance or achievements. It is routine for our internal projection...Click here to read the whole Article (external link)
BrainStorm Stem Cell Therapy Technology Possesses Promising Potential for the Future Treatment of Multiple Sclerosis
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis (MS). In a scientific paper published in the Journal of Molecular Neuroscience, Professors Melamed and Offen’s team from Tel Aviv University studied the effectiveness of human bone marrow derived stem cells induced to differentiate and secrete neurotrophic factors (NTF-SC) as compared to the use of non-differentiated stem cells in a mouse MS model.“This study demonstrated that the transplantation of the NTF-SC, based on our novel differentiation technology, resulted in a delay of disease onset and increased animal survival in the mouse MS model to a greater extent than transplantation of the non-differentiated stem cells. It was shown that the NTF-SC modulate the immune system and protect neuronal cells from toxic insults. The positive results in the mouse MS model indicates that our new technology may serve as a possible approach for the treatment of MS,” commented Professor Daniel Offen, Brainstorm’s chief scientific advisor.“This study demonstrates that Brain...Click here to read the whole Article (external link)
BrainStorm Chief Medical Advisor Interviewed on Israel Radio Broadcast; States Stem Cell Therapy Treatment Ready For Clinical Trials
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that its chief medical advisor, Professor Eldad Melamed, was interviewed on November 9, 2009 on Israel’s most popular radio broadcast, Galei Zahal. The interview was conducted by Yaron Willensky, a respected news talk show host, to discuss the latest achievements, treatment and progress of BrainStorm’s stem cell technology and therapy with respect to neurodegenerative diseases such as ALS and Parkinson’s disease. “The stem cell therapy treatment is ready. We have successfully been able to process autologous adult human mesenchymal stem cells, grow them and differentiate them into other cell types for the treatment of neurodegenerative diseases. We are currently in middle of obtaining approval to begin the first clinical trials on ALS patients in Israel,” stated Professor Melamed during the interview. “Regarding clinical trials for Parkinson’s disease, we are ready to begin,” continued Professor Melamed. “However, we must still complete the regulatory approval process before that can happen.”“The interview with Professor Eldad Melamed, BrainStorm’s chief medical advisor, on Israeli national radio demonstrates the continuing acceptanc...Click here to read the whole Article (external link)
BrainStorm Stem Cell Therapy Treatment Shown To Be More Effective Than Other Current Potential Stem Cell Treatments
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases was shown to be superior to other current potential stem cell treatments. In a scientific paper published in the Israel Medical Association Journal, Ofer Sadan, Eldad Melamed and Daniel Offen, from Tel Aviv University, show the migratory capacity of Neurotrophic Factor Stem Cells (NTF-SC) in animal models of Parkinson’s disease and Huntington disease. The study demonstrated that in a rat model for Parkinson’s disease, the efficacy of NTF-SC was superior to that of mesenchymal stem cells in terms of behavioral, biochemical and histological indices.“The results of this study show that the NTF-SC based treatment is efficacious due to NTF secretion and the stem cell’s migratory capabilities. Since our novel technology is clinically compatible and safe, the study suggests that in the future, cell therapy based on the transplantation of NTF-SC derived from autologous human mesenchymal stem cells should become a preferable option in the treatment of neurodegenerative diseases,” commented Professor Daniel Offen, Brainstorm’s chief scientific advisor.“This study demonstrates that...Click here to read the whole Article (external link)
BRAINSTORM CELL THERAPEUTICS INC Files SEC form 8-K, Unregistered Sale of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. Brainstorm Cell Therapeutics Inc. (the "Company") issued shares of its common stock, par value $0.00005 per share (the "Common Stock"), as follows: On August 10, 2009, the Company issued 71,428 shares of Common Stock to Prodigy Ltd. ("Prodigy") in full satisfaction of the $5,000 liability owed to Prodigy by the Company. The amount payable by the Company to Prodigy was converted into Common Stock at a conversion price of $0.07. On July 15, 2009, the Company issued 357,142 shares of Common Stock to United Business Media ("UBM")in full satisfaction of invoices totaling $16,841.29 and $8,159.71, respective, which invoices related to the provision of EDGAR services to the Company. The amount payable by the Company to UBM was converted into Common Stock at a conversion price of $0.07. On July 8, 2009, the Company issued 142,857 shares of Common Stock to each of Segal Holding and Variance Investment for financial services, in full satisfaction of the $20,000 liability owed to them by the Company. On September 1, 2009, the Company agreed to issue 1,250,000 shares of Common Stock to Emerging Markets Consulting, LLC in exchange for public relations work to be performed for the Company. If the Company terminates the agreement prior to the six month anniversary of the date of such agreement, then 625,000 shares of Common Stock will be canceled and returned to the Company. On October 28, 2009, the Company issued a total of 9,916,667 shares of Common Stock as follows, each party which was assigned the right by ACCBT Corp. under the amendment to the agreement between the Company and ACCBT Corp. to purchase such shares: · 5,000,000 shares to Yosef Sternberg · 1,416,667 shares to Tayside Trading · 1,100,000 shares to Sarah Laufer · 1,000,000 shares to Seastripe Trading Corp. · 1,000,000 shares to Schanzengraben SA · 400,000 shares to PR Diamonds Inc. The i...Click here to read the whole Article (external link)
Integrity Media: Stem Cell Report Released
LAS VEGAS, Oct. 30, 2009 (GLOBE NEWSWIRE) -- A Murphy Analytics report and profile featuring BrainStorm (OTCBB:BCLI - News) and detailing its achievements in stem cell research has been released. This report is of potential interest to investors of leading stem cell equities Geron (Nasdaq:GERN - News), Osiris Therapeutics (Nasdaq:OSIR - News), Aastrom Biosciences (Nasdaq:ASTM - News) and StemCells (Nasdaq:STEM - ...Click here to read the whole Article (external link)
BrainStorm Granted "Outperform" Rating by Murphy Analytics
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI - News) announced today that Murphy Analytics, an equity research group, has Initiated Coverage on Brainstorm and granted Brainstorm with an Outperform Rating. To view Murphy Analytic's report click the link below:http://www.murphyanalytics.com/uploads/BCLI_InitiationRami Efrati, CEO of BrainStorm Cell Therapeutics, states, "We are very pleased with the quality of Murphy Analytics research coverage. The report provides serious investors with an in-depth understanding of our Company and what we believe to be a tremendous opportunity for creating outstanding returns for our shareholders. Murphy Analytics sees upside in both the near and long term and has initiated coverage on BCLI with an Outperform rating."About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (se...Click here to read the whole Article (external link)
BrainStorm Selected to Present at the Israeli Presidential Conference
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News) today announced that it has been selected to present at the Israeli Presidential Conference: Facing Tomorrow 2009 – Tomorrow's Industries exhibition, on October 20-22, at the Congress Center of the Jerusalem International Convention Center in Jerusalem, Israel. BrainStorm’s management and scientific team will be available during the conference to discuss the company, its technology and its progress towards clinical trials. “We are very proud that Brainstorm has been selected to present at the conference as one of the innovators in the stem cell industry,” said Rami Efrati, CEO of Brainstorm. “As the Company nears clinical trials, being selected to present at the conference recognizes the accomplishments of Brainstorm, its management and its scientific team.”Facing Tomorrow is the annual global conference initiated in 2008 by President Shimon Peres. The Conference focuses the mutual tomorrow - investigating the trends that are shaping the future and exploring actions that could and should be undertaken towards the betterment of tomorrow for Israel and the world at large. The Tomorrow's Industries exhibition honors six fields of innovative technologies, including stem cells.About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc. is a...Click here to read the whole Article (external link)
BrainStorm Announces That It Will Reschedule Its Webcast Audio Conference
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News) , announced today that it will reschedule the webcast audio conference to update shareholders on its strategy and report on the way forward towards clinical trials. This event will be rescheduled for a later date to be announced soon.We apologize for any inconvenience.About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist ...Click here to read the whole Article (external link)
Brainstorm Announces Milestone Towards ALS Clinical Trials
NEW YORK & PETACH TIKVAH, ISRAEL--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therapeutics, announced today that bone marrow cells taken from ALS patients were capable of differentiating into nerve-supporting cells. The company tested ALS patients' bone marrow stem cells in order to confirm that these stem cells could undergo BrainStorm’s differentiation procedure to secrete NeuroTrophic Factors (NTF) and used for treatment by back transplantation into the patients.The experiments performed at BrainStorm Cell Therapeutics’ research laboratories showed that the stem cells isolated from bone marrow of healthy donors and ALS patients were similar, as indicated by all the morphological and biochemical parameters tested. In addition, the cellular expansion potential of stem cells from the healthy donors and from the patients was comparable. Most important, cells from both, the healthy donors and the patients, secreted NeuroTrophic Factors (NTF) after applying Brainstorm’s unique differentiation protocols.BrainStorm will now complete all of its preparations for pre-clinical trials to be followed by clinical trials based on the company's proposed stem cell therapy.Prof. Daniel Offen, Brainstorm’s Chief Scientist, said: ”The differentiated stem cells express specific proteins characterist...Click here to read the whole Article (external link)
Would you like to leave a comment about Brainstorm Cell Therapeutics Inc. BCLI/BCLI.OB
Find out what social network information about Brainstorm Cell Therapeutics Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Brainstorm Cell Therapeutics Inc. there is more great information available at Realpennies.com